Non-interventional, Multi-Centre, Post-Authorisation Safety Study With Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients
Phase of Trial: Phase IV
Latest Information Update: 16 Jul 2018
At a glance
- Drugs Turoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 03 Jul 2018 Planned End Date changed from 15 Jun 2020 to 14 Jun 2021.
- 03 Jul 2018 Planned primary completion date changed from 31 May 2020 to 15 Jun 2020.
- 03 Jul 2018 Status changed from not yet recruiting to recruiting.